Non-Small Cell Lung Cancer; Review of Mutations and Tyrosine Kinase Inhibitors

Author Info

Dhara Dave Basheer Mohammed Janakikeerthika Dharmarpandi Darshit Dave Rohit Saralaya Praveen Tumula

Corresponding Author

Dhara Dave
Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA

A B S T R A C T

Lung cancer is the leading cause of cancer-related death in the United States and the incidence of this in never smokers is about 15-20% in males and about 50% in females. Non-small cell lung carcinoma (NSCLC) constitutes about 75% to 80% of these cancers and is more common than small cell lung carcinoma (SCLC) in never smokers. Treatment of NSCLC has been rapidly evolving with the discovery of targetable mutations like EGFR, and ALK. Despite this, prognosis of NSCLC remains guarded given diagnosis at an advanced stage as well as patient factors like age and comorbidities. The standard of care should include therapy customized to suit the patient. In this review article we report the first known case of checkpoint mutation seen in a patient with NSCLC and summarize the common mutations along with targeted therapy with tyrosine kinase inhibitors.

Article Info

Article Type

Review Article

Publication history

Received: Tue 07, Jun 2022
Accepted: Mon 20, Jun 2022
Published: Fri 01, Jul 2022

Copyright

© 2023 Dhara Dave. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.AJMC.2022.01.01